Findings from recently held two studies reveal that adalimumab reduces the risk of hospitalization as well as major surgery in patients suffering from Crohn’s disease (CD). The year long phase 3 trial (named CHARM) found that adalimumab was effective in improving the condition of patients with Crohn’s disease. There was a reduction in hospitalizations by half. Moreover, majority of Crohn’s disease patients undergo surgery. The results of the trial showed surgeries related to CD were reduced by as much as 90% in patients receiving adalimumab as compared to those receiving placebo. This makes the drug a cost-effective solution to the disorder. The study received support in the form of industry grants from Abbott Laboratories.